SCHEMBL2809024

SCHEMBL2809024

c1nc(NC2CCc3c(cnc4[nH]ncc34)C2)c2cc[nH]c2n1

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 2/20 0.54
IRAK4 Q9NWZ3 1/20 0.48
GRIN2B Q13224 11/20 0.43
CYP2D6 P10635 5/20 0.43
KCNH2 Q12809 7/20 0.42
JAK3 P52333 4/20 0.42
JAK1 P23458 1/20 0.42
TEC P42680 1/20 0.42
TXK P42681 1/20 0.42
BLK P51451 1/20 0.42
BMX P51813 1/20 0.42
BTK Q06187 1/20 0.42
ITK Q08881 1/20 0.42
ERBB4 Q15303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2808084 0.90 HPGDS (0.60) HPGDSGRIN2BCYP2D6KCNH2
SCHEMBL2805753 0.83 HPGDS (0.46) HPGDSGRIN2BCYP2D6KCNH2
SCHEMBL2804134 0.79 HPGDS (0.44) HPGDSGRIN2BCYP2D6KCNH2
SCHEMBL8929835 0.78 HPGDS (0.63) HPGDSIRAK4GRIN2BCYP2D6KCNH2
Hydrochloric Acid SCHEMBL8929253 0.77 HPGDS (0.61) HPGDSIRAK4GRIN2BCYP2D6KCNH2
SCHEMBL12316008 0.76 HPGDS (0.43) HPGDSGRIN2BCYP2D6KCNH2
SCHEMBL12315722 0.74 MALT1 (0.35) HPGDSGRIN2B
SCHEMBL1818948 0.74 HPGDS (0.88) HPGDSIRAK4GRIN2BCYP2D6KCNH2
SCHEMBL12316007 0.74 HPGDS (0.36) HPGDS
SCHEMBL12316006 0.74 HPGDS (0.36) HPGDSJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 HPGDS 167/4885IRAK4 2272/4885GRIN2B 2425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.